COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study of ARC1779 in Patients With Acute Myocardial Infarction Undergoing PCI (vITAL-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00507338
Recruitment Status : Terminated
First Posted : July 26, 2007
Last Update Posted : January 9, 2009
Information provided by:
Archemix Corp.

Brief Summary:
ARC1779 is a novel drug being tested in patients undergoing angioplasty and stenting as their primary treatment for heart attack.

Condition or disease Intervention/treatment Phase
Acute Myocardial Infarction Procedure: PCI Phase 2

Detailed Description:
Adjunctive anti-thrombotic therapy for PCI of AMI may be improved by incorporation of a novel anti-platelet therapeutic principle, von Willebrand Factor antagonism. ARC1779 is a therapeutic oligonucleotide ("aptamer") which blocks the binding of the A1 domain of vWF to the platelet GPIb receptor, and thereby modulates platelet adhesion, activation, and aggregation under the high shear conditions of coronary arterial stenosis and plaque rupture. This study is intended to provide dose-ranging and clinical proof of concept for ARC1779 in a primary PCI population.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2 Study of an Aptameric Von Willebrand Factor Antagonist, ARC1779, in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention
Study Start Date : October 2007
Actual Primary Completion Date : February 2008
Actual Study Completion Date : February 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Attack

Arm Intervention/treatment
Experimental: ARC1779 low dose
0.1 mg/kg
Procedure: PCI
early PCI for NSTEMI; primary PCI for STEMI

Experimental: ARC1779 mid dose
0.3 mg/kg
Procedure: PCI
early PCI for NSTEMI; primary PCI for STEMI

Experimental: ARC1779 high dose
1.0 mg/kg
Procedure: PCI
early PCI for NSTEMI; primary PCI for STEMI

Active Comparator: abciximab
labeled regimen for primary PCI
Procedure: PCI
early PCI for NSTEMI; primary PCI for STEMI

Primary Outcome Measures :
  1. adequacy of reperfusion [ Time Frame: 48 hours post-PCI ]

Secondary Outcome Measures :
  1. bleeding [ Time Frame: PCI to hospital discharge ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • troponin-positive NSTEMI, with diagnostic symptoms and/or ECG abnormalities present within the preceding 24 hours, and a planned "early invasive" management strategy
  • STEMI, with planned primary PCI

Exclusion Criteria:

  • History of bleeding diathesis or evidence of active abnormal bleeding within the previous 30 days
  • Received treatment with fibrinolytic or GPIIb/IIIa antagonist drugs within the preceding 72 hours
  • Received anticoagulant therapy with a low molecular weight heparin within the preceding 8 hours
  • Severe hypertension (systolic blood pressure >200 mmHg or diastolic blood pressure >110 mmHg) not adequately controlled on antihypertensive therapy
  • Major surgery or trauma within the preceding 6 weeks
  • History of stroke within 30 days or any history of hemorrhagic stroke
  • End-stage renal disease (ESRD) with dependency on renal dialysis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00507338

Layout table for location information
Russian Federation
Archemix Investigational Site
St. Petersburg, Russia, Russian Federation, 199106
Sponsors and Collaborators
Archemix Corp.
Layout table for investigator information
Study Chair: Michael Gibson, MD Harvard Medical School, Beth Israel Deaconess Medical Center
Principal Investigator: Franz-Josef Neumann, MD Herz-Zentrum Bad Krozingen

Layout table for additonal information
Responsible Party: James Gilbert, MD/Chief Medical Officer, Archemix, Corp. Identifier: NCT00507338    
Other Study ID Numbers: ARC1779-003
First Posted: July 26, 2007    Key Record Dates
Last Update Posted: January 9, 2009
Last Verified: January 2009
Keywords provided by Archemix Corp.:
percutaneous coronary intervention
Additional relevant MeSH terms:
Layout table for MeSH terms
Myocardial Infarction
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases